Writing Group Disclosures
| Writing group member | Employment | Research grant | Other research support | Speakers’ bureau/honoraria | Expert witness | Ownership interest | Consultant/advisory board | Other |
|---|---|---|---|---|---|---|---|---|
| Reena Mehra | Cleveland Clinic Foundation | NIH*; American Academy of Sleep Medicine* | None | None | None | None | None | None |
| Mina K. Chung | Cleveland Clinic | AHA†; NIH† | None | None | None | None | None | None |
| Dobromir Dobrev | University Duisburg–Essen Institute of Pharmacology (Germany) | None | None | None | None | None | None | None |
| Chandra L. Jackson | National Institutes of Health | None | None | None | None | None | None | None |
| Vaishnavi Kundel | Icahn School of Medicine at Mount Sinai | None | None | None | None | None | None | None |
| Dominik Linz | Maastricht University Medical Centre (Netherlands) | None | None | None | None | None | None | None |
| Brian Olshansky | University of Iowa Hospitals and Clinics | None | None | None | None | None | AstraZeneca DSMB* | None |
| Nancy S. Redeker | Yale School of Nursing | None | None | None | None | None | None | None |
| Susan Redline | Brigham and Women’s Hospital | NIH (multiple NIH grants on sleep)† | None | None | None | None | Apnimed, Inc†; Eli Lilly*; Jazz Pharma* | None |
| Prashanthan Sanders | University of Adelaide and Royal Adelaide Hospital Centre for Heart Rhythm Disorders (Australia) | None | None | None | None | None | None | None |
| Virend K. Somers | Mayo Clinic | NIH (funds to institution)†; Sleep Number (funds to institution)†; Medtronic (equipment to institution)†; Itamar (equipment to institution)† | None | None | None | None | Bayer*; Jazz Pharmaceuticals†; Respicardia*; Huxley Medical*; ResMed* | None |
This table represents the relationships of writing group members that may be perceived as actual or reasonably perceived conflicts of interest as reported on the Disclosure Questionnaire, which all members of the writing group are required to complete and submit. A relationship is considered to be “significant” if (a) the person receives $10 000 or more during any 12-month period, or 5% or more of the person’s gross income; or (b) the person owns 5% or more of the voting stock or share of the entity, or owns $10 000 or more of the fair market value of the entity. A relationship is considered to be “modest” if it is less than “significant” under the preceding definition.
*
Modest.
†
Significant.